CardioFocus announced the completion of clinical cases with its QuickShot Nav large-area focal pulsed field ablation (PFA) ...

We recently published a list of the 10 Best Dividend Monarchs to Invest in Now. In this article, we are going to take a look ...

Abbott designed the Volt PFA catheter for maneuverability, efficient ablation and thermal risk mitigation, said Dr.

GAAP diluted EPS of $0.76; adjusted diluted EPS of $1.09 First-quarter reported sales growth of 4.0 percent; organic sales growth of 6.9 percent or ...

Guidance: Abbott reaffirms full-year 2025 adjusted EPS of $5.05-$5.25 versus a consensus of $5.15, with organic sales growth ...

Abbott Laboratories reported a strong start to 2025 with significant growth in sales and EPS, exceeding market expectations.

Pulse Biosciences is developing nsPFA technology for cardiac ablation to treat AFib and for ablating benign thyroid nodules.

The system, which has received CE Mark approval in Europe, adds to an increasingly crowded field of PFA technologies.

Designed to overcome limitations of existing systems, Abbott's Volt™ PFA System provides a new therapy option for people battling heart rhythm disorders. Sun Pharma to Acquire Checkpoint ...

Designed to overcome limitations of existing systems, Abbott's Volt™ PFA System provides a new therapy option for people battling heart rhythm disorders. Sun Pharma to Acquire Checkpoint Therapeutics ...